Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (5061)	8/4/1998 7:42:00 AM
From: Henry Niman	Respond to of 6136

Here's what Paine Webber said last week about scrips and market share: Solid monthly scrips for June ú For the month of June 1998, Viracept prescriptions were as follows: - Total prescriptions were 49,801 compared with 48,087 in May (3.6% unadjusted growth, -2.5% adjusted growth) - New prescriptions were 17,955 compared with 17,756 in May (1.1% unadjusted growth, -5.0% adjusted growth) - Refills were 31,846 compared with 30,331 in May (5.0% unadjusted growth, -1.1% adjusted growth). ú Viracept continues to gain market share (see Chart 2). Viracept has increased its market share from 31.3% in May to 31.8% in June for total prescriptions within the protease inhibitor class. As we have been anticipating, Viracept continues to close the gap with Crixivan. In our analysis, total Crixivan scrips have declined by 9% year over year. Its market share has dropped considerably relative to last summer (55- 60%). For the period from May to June, Crixivan's market share in total scrips has dropped to 33.6% from 33.9%.